NICHD fetal growth calculators now available
Two calculators for practitioners to estimate fetal growth percentiles, velocity and account for racial and ethnic variation from the NICHD are now available.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) offers two calculators to help providers estimate the growth of a fetus. Both calculators consider racial and ethnic variations for a more accurate estimate than conventional growth charts. They are both results of NICHD’s Fetal Growth Study, which aimed and continues to aim for the establishment of evidence-based standards for normal fetal growth in the United States.
The Fetal Growth Velocity Calculator
The NICHD Fetal Growth Studies velocity calculator is designed to estimate fetal growth velocity between 11 0/7 to 41 6/7 weeks of gestation for one baby. Four estimates of estimated fetal weight (EFW) percentiles can be obtained and depend on the ultrasound measurements entered, including head circumference (HC), biparietal diameter (BPD), abdominal circumference (AC) and femur length (FL).
Fetal Growth Calculator
This calculator uses data from the NICHD Fetal Growth Study to calculate EFW for one fetus between 10 weeks 0 days and 41 weeks 6 days of pregnancy. The calculator can provide 4 estimates of EFW percentiles depending on the ultrasound measurements entered. A PDF of the Percentile Range Spreadsheet, provided by the NICHD, can be found here.
More information on the calculators and the NICHD’s Fetal Growth Study can be found here.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Increasing ondansetron use reported against NVP in the United States
October 29th 2024Despite being recommended as a third-line therapy, rates of ondansetron use to treat nausea and vomiting in pregnancy have increased, making it the most common prescription antiemetic against this condition in the United States.
Read More
